Advertisement

Kidney Cancer pp 399-408 | Cite as

Targeted Treatment of Renal Cell Carcinoma

  • Matteo Santoni
  • Alessia Cimadamore
  • Liang Cheng
  • Antonio Lopez-Beltran
  • Marina Scarpelli
  • Nicola Battelli
  • Rodolfo Montironi
Chapter

Abstract

The management of patients with metastatic RCC (mRCC) has been completely changed in the last decade by the introduction of novel molecularly targeted approaches. Although partial or radical nephrectomy still remains the standard approach for patients with localized RCC, systemic therapies are recommended in patients with mRCC. Till 2005, cytokine therapies represented the gold standard but were associated with a poor toxicity profile and a low response rate. Successively, the growing knowledge of the key role of angiogenesis in the development and progression of mRCC has led to the development of several targeted agents, which have increased the life expectancy of these patients. In this chapter, we describe the main agents currently used into daily clinical practice and the results of the clinical studies that have led to their approval in patients with mRCC.

Keywords

Renal cell carcinoma Molecular markers Genetic alteration Target therapy Immunotherapy Vascular endothelial growth factor (VEGFR) Tyrosine kinase inhibitors (TKI) mTOR pathway 

References

  1. 1.
    Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–9.PubMedGoogle Scholar
  2. 2.
    Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144–50.  https://doi.org/10.1200/JCO.2009.26.7849.CrossRefPubMedGoogle Scholar
  3. 3.
    Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137–43.  https://doi.org/10.1200/JCO.2009.26.5561.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hainsworth JD, Spigel DR, Burris HA III, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010;28:2131–6.  https://doi.org/10.1200/JCO.2009.26.3152.CrossRefPubMedGoogle Scholar
  5. 5.
    Negrier S, Gravis G, Perol D, Chevreau C, Delva R, Bay JO, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011;12:673–80.  https://doi.org/10.1016/S1470-2045(11)70124-3.CrossRefPubMedGoogle Scholar
  6. 6.
    Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 2014;32:752–9.  https://doi.org/10.1200/JCO.2013.50.5305.CrossRefPubMedGoogle Scholar
  7. 7.
    Harshman LC, Barbeau S, McMillian A, Srinivas S. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013;11:100–6.  https://doi.org/10.1016/j.clgc.2012.12.002.CrossRefPubMedGoogle Scholar
  8. 8.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.  https://doi.org/10.1056/NEJMoa060655.CrossRefPubMedGoogle Scholar
  9. 9.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312–8.  https://doi.org/10.1200/JCO.2008.19.5511.CrossRefPubMedGoogle Scholar
  10. 10.
    Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(8):760–7.  https://doi.org/10.1200/JCO.2013.50.3961.CrossRefPubMedGoogle Scholar
  11. 11.
    Haas NB, Manola J, Uzzo RG, Atkins MB, Wilding G, Pins M, et al. Initial results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. J Clin Oncol. 2015;33. Suppl 7; abstr 403:403.  https://doi.org/10.1200/jco.2015.33.7_suppl.403.CrossRefGoogle Scholar
  12. 12.
    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–90.  https://doi.org/10.1200/JCO.2008.20.1293.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al., S-TRAC investigators. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246–2254. doi:  https://doi.org/10.1056/NEJMoa1611406.CrossRefGoogle Scholar
  14. 14.
    Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8.  https://doi.org/10.1200/JCO.2009.23.9764.CrossRefPubMedGoogle Scholar
  15. 15.
    Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49:1287–96.  https://doi.org/10.1016/j.ejca.2012.12.010.CrossRefPubMedGoogle Scholar
  16. 16.
    Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014;32:1412–8.  https://doi.org/10.1200/JCO.2013.50.8267.CrossRefPubMedGoogle Scholar
  17. 17.
    Hainsworth JD, Rubin MS, Arrowsmith ER, Khatcheressian J, Crane EJ, Franco LA. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clin Genitourin Cancer. 2013;11:270–5.  https://doi.org/10.1016/j.clgc.2013.04.006.CrossRefPubMedGoogle Scholar
  18. 18.
    Motzer R, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E,et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). J Clin Oncol. 2017;35 Suppl 15:abstr 4507. doi:  https://doi.org/10.1200/JCO.2017.35.15_suppl.4507.CrossRefGoogle Scholar
  19. 19.
    Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.  https://doi.org/10.1016/S0140-6736(11)61613-9.CrossRefPubMedGoogle Scholar
  20. 20.
    Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14:552–62.  https://doi.org/10.1016/S1470-2045(13)70093-7.CrossRefPubMedGoogle Scholar
  21. 21.
    Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14:1287–94.  https://doi.org/10.1016/S1470-2045(13)70465-0.CrossRefPubMedGoogle Scholar
  22. 22.
    Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al., METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917–927. doi:  https://doi.org/10.1016/S1470-2045(16)30107-3.CrossRefGoogle Scholar
  23. 23.
    Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35:591–7.  https://doi.org/10.1200/JCO.2016.70.7398.CrossRefPubMedGoogle Scholar
  24. 24.
    Molina AM, Hutson TE, Larkin J, Gold AM, Wood K, Carter D, et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol. 2014;73:181–9.  https://doi.org/10.1007/s00280-013-2339-y.CrossRefPubMedGoogle Scholar
  25. 25.
    Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909–18.  https://doi.org/10.1200/JCO.2004.08.185.CrossRefPubMedGoogle Scholar
  26. 26.
    Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI- 779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336–47.  https://doi.org/10.1200/JCO.2004.08.116.CrossRefPubMedGoogle Scholar
  27. 27.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.  https://doi.org/10.1056/NEJMoa066838.CrossRefPubMedGoogle Scholar
  28. 28.
    Ravaud A, Barrios CH, Alekseev B, Tay MH, Agarwala SS, Yalcin S, et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon a-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2015;26:1378–84.  https://doi.org/10.1093/annonc/mdv170.CrossRefPubMedGoogle Scholar
  29. 29.
    Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:2765–72.  https://doi.org/10.1200/JCO.2013.54.6911.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13.  https://doi.org/10.1056/NEJMoa1510665.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 Study. J Clin Oncol. 2017;35:3851–8.  https://doi.org/10.1200/JCO.2016.72.1985.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Matteo Santoni
    • 1
  • Alessia Cimadamore
    • 2
  • Liang Cheng
    • 3
  • Antonio Lopez-Beltran
    • 4
  • Marina Scarpelli
    • 5
  • Nicola Battelli
    • 1
  • Rodolfo Montironi
    • 5
  1. 1.Oncology Unit, Macerata HospitalMacerataItaly
  2. 2.Institute of Pathological Anatomy and Histopathology, University of the Marche RegionAnconaItaly
  3. 3.Departments of Pathology, Urology, and Laboratory MedicineIndiana University School of MedicineIndianapolisUSA
  4. 4.Department of Pathology and SurgeryCordoba University School of MedicineCórdobaSpain
  5. 5.Institute of Pathological Anatomy and Histopathology, United HospitalsAnconaItaly

Personalised recommendations